Clinical Trial

The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Evaluate the efficacy and safety of Trilaciclib for myeloprotection prior to chemotherapy in advanced cholangiocarcinoma or pancreatic cancer.
Trial Details
NCT Number NCT07160283
Lead Sponsor The Second Affiliated Hospital of Shandong First Medical University
Conditions Biliary Tract Neoplasms, Pancreatic Neoplasms
Enrollment 96 participants
Start Date 2025-09-01
Primary Completion 2027-09-01 (estimated)
Study Completion 2028-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-08